Advertisement

Topics

AbbVie Gets FDA Priority Review For Elagolix; Hikes Dividend - Quick Facts

07:44 EDT 27 Oct 2017 | RTTNews

AbbVie (ABBV) in cooperation with Neurocrine Biosciences, Inc. (NBIX), said that the U.S. Food and Drug Administration has granted priority review for elagolix.

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: AbbVie Gets FDA Priority Review For Elagolix; Hikes Dividend - Quick Facts

NEXT ARTICLE

More From BioPortfolio on "AbbVie Gets FDA Priority Review For Elagolix; Hikes Dividend - Quick Facts"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.